Literature DB >> 9333627

[Oral DMSO therapy in 3 patients with lipoidproteinosis. Results of long-term therapy].

E Ozkaya-Bayazit1, G Ozarmağan, C Baykal, T Uluğ.   

Abstract

Lipoid proteinosis is a rare autosomal recessive disorder with a chronic, benign course. There is no generally accepted systemic therapy apart from the experimental oral use of dimethyl sulphoxide (DMSO) and etretinate in two single cases. We treated two sisters and an unrelated man with lipoid proteinosis with longterm oral DMSO (60 mg/kg/d). At the end of an average treatment time of 3 years, DMSO was withdrawn because it produced no beneficial effects with regard to their skin, mucosal lesions or hoarseness. Additionally, one patient showed progression of her disease with worsening hoarseness and onset of dyspnea, requiring surgical removal of vocal cord infiltrates. Three patients with lipoid proteinosis failed to show any beneficial response to long term treatment with DMSO.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333627     DOI: 10.1007/s001050050613

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  3 in total

1.  Two Egyptian cases of lipoid proteinosis successfully treated with acitretin.

Authors:  Ola Ahmed Bakry; Rehab Monir Samaka; Nanees Shawky Houla; Mohamed Ahmed Basha
Journal:  J Dermatol Case Rep       Date:  2014-03-31

2.  Cryosurgery (N2O) Application to Remove Lip Lesions of Lipoid Proteinosis Syndrome: A Case Report.

Authors:  Amir Mansour Shirani
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2008-08-15

3.  Acitretin treatment for lipoid proteinosis.

Authors:  Ozgür Gündüz; Neriman Sahiner; Pınar Atasoy; Cağrı Senyücel
Journal:  Case Rep Dermatol Med       Date:  2012-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.